Skip to main content
All articles

Site Operations

Mobile research units: which visits actually move — and which have to stay in clinic

By Julio G. Martinez-Clark Published November 14, 2026 Updated November 14, 2026 5 min read

Start with the visit list, not the vehicle

Sites usually start with the vehicle: what it costs, how it is equipped, where it can park. Sponsors start somewhere else. They ask which specific visits, for which specific protocol, the unit will cover — and what happens when something goes wrong during one of them.

That is why the first document in a mobile-unit proposal should be a visit list, not a brochure. Take the schedule of assessments and sort every visit into three buckets:

  • Moves safely: routine assessments that need no escalation pathway beyond basic monitoring — vital signs, phlebotomy, ECGs, questionnaires, and medication dispensing where the protocol allows it.
  • Stays in clinic: infusions, invasive or complex procedures, first-dose observations, and any visit where an adverse event would need immediate on-site intervention.
  • Sponsor decides: visits that are technically portable but change the risk or data picture — for example, assessments tied to a primary endpoint, or visits the protocol currently describes as site-based.

A sponsor can approve, amend, or price a list. It cannot do any of those things with a general claim that the van improves access.

The two failure modes

The first failure mode is staffing. One coordinator cannot run a route and run the clinic on the same day. A mobile visit still needs source documentation, investigational product (IP) accountability where applicable, and a clinician reachable for questions — and the participants who stayed at the clinic still need their visits covered. Sites that staff the van by borrowing from the clinic create delays in both places and burn out the coordinator doing double duty. Staff the route as its own assignment, with its own coverage, or do not run it that day.

The second failure mode is sequence. A van announced as a recruitment tool before the sponsor has signed off on the model creates a promise the site may not be able to keep. Participants enroll expecting home-area visits; the sponsor then limits which visits can move, or declines the model for an endpoint visit, and the site has to walk the promise back. Sponsor sign-off comes first — on the visit list, the safety plan, and the budget — and recruitment language comes after.

What a sponsor needs to see

A credible mobile-unit proposal answers five questions without being asked twice:

  • Cold chain: how IP and samples are stored, temperature-monitored, and documented in transit, with the same records the clinic keeps.
  • Safety monitoring: who is present at each visit type, what escalation looks like from the field, and how an adverse event is reported and documented the same day.
  • Source documentation: where data is captured, how it enters the trial record, and how a monitor reviews it — the audit trail cannot depend on where the visit happened.
  • Equipment: which devices travel, how they are calibrated, and how calibration and maintenance logs follow the equipment.
  • Cost: what the model costs per visit or per route day, stated as budget lines the sponsor can approve, rather than absorbed quietly until the site cannot sustain it.

None of these is exotic. They are the same questions a sponsor asks about the clinic, asked about a moving location. Sites that answer them in clinic terms — same procedures, same documentation, different address — make the decision easy to approve.

Mobile is not the same as transported

Bringing the site to the participant is a different model from bringing the participant to the site, and the two should not be confused in a budget or a protocol. Transportation support solves distance for a participant who can still be seen in clinic. A mobile unit changes where the visit itself happens, which is why it needs protocol language, safety planning, and sponsor agreement that a ride to the clinic does not.

That distinction is also the opportunity. For participants who cannot travel repeatedly — because of distance, work, caregiving, or the condition under study — a mobile visit for the routine assessments can be the difference between staying in a trial and dropping out. Retention is where the model earns its cost, and retention is a sponsor outcome, not just a site convenience.

How this works in practice

At Amavita Research, our Miami cardiovascular trial site, we care for more than 18,000 active cardiology patients, and our record includes zero United States Food and Drug Administration (FDA) Form 483 findings. Access is a real constraint for that population, which is exactly why the discipline matters: sort the visits before buying the model, staff the route as its own job, and get the sponsor's sign-off on a specific visit list — with cold chain, safety monitoring, and source documentation handled — before a single participant is promised a visit closer to home. That is how a mobile unit stops being a recruitment claim and becomes a model a sponsor can approve.

Julio G. Martinez-Clark is chief executive officer of Amavita Research Services, a Miami cardiovascular trial site, and chief executive officer of bioaccess, a first-in-human contract research organization.

Next step

Sponsors: see what Amavita Research can run

Amavita Research is a Miami cardiovascular trial site with 18,000+ active cardiology patients and zero United States Food and Drug Administration (FDA) Form 483 findings. See our site capabilities or talk with our sponsor team.

By Julio G. Martinez-Clark · Last updated November 14, 2026. This article is site-operations education and is not medical advice or a regulatory recommendation.